Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

May

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL

FDA Approves Combination Regimen for Newly Diagnosed AML

Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors